13G Filing: Nexthera Capital and Catalyst Biosciences Inc. (CBIO)

Item 1(a).

Name of Issuer:

Catalyst Biosciences, Inc. (the “Issuer”).

Item 1(b).

Address of Issuer’s Principal Executive Offices:

260 Littlefield Avenue

South San Francisco, California 94080

Item 2(a).

Name of Persons Filing:

This Statement is filed on behalf of each of the following persons (collectively, the “Reporting Persons”):

i)

Nexthera Capital LP (“Nexthera Capital”);

ii)

Nexthera Capital GP LLC (“Nexthera GP”);

iii)

Daniel Malek (“Mr. Malek”); and

iv)

Ori Hershkovitz (Mr. Hershkovitz”).

Nexthera GP is the general partner of Nexthera Capital. Mr. Malek and Mr. Hershkovitz are the managing members Nexthera GP By virtue of these relationships, each of Nexthera GP, Mr. Malek and Mr. Hershkovitz may be deemed to have voting and dispositive power with respect to the shares of Common Stock (as defined below) beneficially owned by Nexthera Capital.

Item 2(b).

Address of Principal Business Office or, if None, Residence:

The address of the principal business office of each of the Reporting Persons is 900 Third Avenue, Suite 201.1, New York, New York 10022.

Item 2(c).

Citizenship:

i)

Nexthera Capital is a Delaware limited partnership;

ii)

Nexthera GP is a Delaware limited liability company;

iii)

Mr. Malek is a citizen of Belgium; and

iv)

Mr. Hershkovitz is a citizen of Israel.

Item 2(d).

Title of Class of Securities:

Common Stock, par value $0.001 per share (the “Common Stock”)

Item 2(e).

CUSIP Number:

14888D208

13G Filing: Nexthera Capital and Catalyst Biosciences Inc. (CBIO)

Published on December 29, 2017 at 10:30 am by Insider Monkey Staff in Hedge Funds

Page 6 of 9 – SEC Filing

Follow Gyre Therapeutics Inc. (NASDAQ:GYRE)

Follow Gyre Therapeutics Inc. (NASDAQ:GYRE)

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Published on December 13, 2024 at by Inan Dogan, PhD

A New Dawn is Coming to U.S. Stocks

Published on November 16, 2024 at by Insider Monkey Staff